Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 67383

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease

Jose María Huguet, Xavier Cortés, Marta Maia Bosca-Watts, Marian Aguas, Nuria Maroto, Lidia Martí, Cirilo Amorós, Jose María Paredes

Abstract

BACKGROUND

24,900 Results Any time

CT-P13 (Inflectra™, Remsima™) monitoring in patients with ...

https://pubmed.ncbi.nlm.nih.gov/27435444

The approval of **infliximab biosimilars Remsima**™ and Inflectra™ (CT-P13) for patients with **inflammatory bowel disease** (IBD) is a promising step to reduce treatment costs. Since monitoring of Remicade™ serum trough levels and anti-Remicade™ immunogenicity hold an important significance in treatment modalities, no data about monitoring of drug serum trough ...

Cited by: 7 **Author:** Kornelius Schulze, Nadine Koppka, F...

Publish Year: 2016

Switching from Remicade® to Remsima® is well Tolerated ...

https://pubmed.ncbi.nlm.nih.gov/27660339

Abstract. Background and aims: A **biosimilar** version of **infliximab** [CT-P13/Remsima®] recently entered the European market. The clinical **data** on its use in **inflammatory bowel disease** [IBD] are sparse, especially on switching from the originator Remicade®. In this study, we aimed to prospectively investigate the feasibility, safety and immunogenicity of switching from **Remicade** to **Remsima** in a **real-life** ...

Cited by: 97 **Author:** Lydia C. T. Buer, Lydia C. T. Buer, Bjø...

Publish Year: 2016

Clinical experience with infliximab biosimilar Remsima (CT ...

https://www.ncbi.nlm.nih.gov/pubmed/27134662

Based on current **data**, **CT-P13** seems to be efficacious and generally well tolerated in **IBD** especially in patients who are naïve to biological therapy. Knowledge with regard to interchangeability between **CT-P13** and the originator **infliximab** is however, still rather sparse and more **data** are desired.

Cited by: 21 **Author:** Jørgen Jahnsen, Jørgen Jahnsen

Publish Year: 2016

Post-marketing analysis for biosimilar CT-P13 in ...

https://pubmed.ncbi.nlm.nih.gov/33450057

Background and aim: **CT-P13**, an **infliximab** (IFX) biosimilar, was approved for treatment of inflammatory bowel disease. However, no comparison with the originator IFX in this indication has

Infliximab biosimilar CT-P13 is interchangeable with its ...

https://pubmed.ncbi.nlm.nih.gov/31422647

Background/aims: An interim analysis of post-marketing surveillance of **CT-P13**, an **infliximab biosimilar**, was performed to evaluate its safety and efficacy in Japanese patients with **inflammatory bowel disease**. Methods: Patients were prospectively enrolled between November 2014 and March 2017, after the launch of **CT-P13** in Japan, and case report forms of patients followed for at least 4 …

Cited by: 4 **Author:** Tomoo Nakagawa, Taku Kobayashi, Kiyo…

Publish Year: 2019

7,780 Results Any time

Infliximab biosimilar CT-P13 is interchangeable with its ...

https://pubmed.ncbi.nlm.nih.gov/31422647

Background/aims: An interim analysis of post-marketing surveillance of **CT-P13**, an **infliximab biosimilar**, was performed to evaluate its safety and efficacy in Japanese patients with **inflammatory bowel disease**. Methods: Patients were prospectively enrolled between November 2014 and March 2017, after the launch of **CT-P13** in Japan, and case report forms of patients followed for at least 4 months ...

Cited by: 4 **Author:** Tomoo Nakagawa, Taku Kobayashi, Kiyohir...
Publish Year: 2019

CT-P13 (Inflectra™, Remsima™) monitoring in patients with ...

https://pubmed.ncbi.nlm.nih.gov/27435444

The approval of **infliximab biosimilars Remsima**™ and Inflectra™ (CT-P13) for patients with **inflammatory bowel disease** (IBD) is a promising step to reduce treatment costs. Since monitoring of Remicade™ serum trough levels and anti-Remicade™ immunogenicity hold an important significance in treatment modalities, no data about monitoring of drug serum trough levels or anti-drug antibody ...

Cited by: 9 **Author:** Kornelius Schulze, Nadine Koppka, Frederik...
Publish Year: 2016

Clinical experience with infliximab biosimilar Remsima (CT ...

https://www.ncbi.nlm.nih.gov/pubmed/27134662

Based on current **data, CT-P13** seems to be efficacious and generally well tolerated in **IBD** especially in patients who are naïve to biological therapy. Knowledge with regard to interchangeability between **CT-P13** and the originator **infliximab** is however, still rather sparse and more **data** are desired.

Cited by: 21 **Author:** Jørgen Jahnsen, Jørgen Jahnsen
Publish Year: 2016

Switching from infliximab to biosimilar in inflammatory ...

https://journals.sagepub.com/doi/full/10.1177/1756284819842748

Apr 15, 2019 · In 2017, the extension study of **PLANETRA** and PLANETAS showed that switching from **RP** to its **biosimilar CT-P13** is possible without negative effects on safety or efficacy in patients with AS. 65,66 Furthermore, switching from the **IFX RP** to **CT-P13** after 1 year of **IFX RP** treatment showed continued comparable efficacy, immunogenicity and safety, to maintenance of **CT-P13** treatment during the second year of the treatment. 66 In **PLANETRA**, ...